POLYTECH Health & Aesthetics GmbH, a Germany-based company involved in breast aesthetics, reconstruction, and body contouring, and the London Regenerative Institute (LRI), a clinician-led institute specialising in regenerative medicine, adipose tissue processing and translational education, announced Friday a worldwide partnership to advance the use of adipose tissue-based techniques in aesthetic and reconstructive surgery.
This partnership brings together two complementary capabilities. POLYTECH says that it contributes an established international commercial infrastructure, long-standing relationships with plastic and reconstructive surgeons, and a training model focused on hands-on education. The London Regenerative Institute contributes a clinician-led research and development environment with a focus on adipose tissue processing, regenerative protocols and structured clinical training.
Plans for the partnership include launching a portfolio, as well as physician education initiatives, workshops, and clinical training programmes.
Acumen Pharmaceuticals phase 2 Alzheimer's trial misses primary endpoint
Immunome secures EMA validation of varegacestat application for desmoid tumors
FDA approves Sun Pharma's ILUMYA for psoriatic arthritis
Alkermes initiates phase 2 study of ALKS 7290 for major depressive disorder
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
HR HealthCare establishes charitable arm
Sobi presents phase 3 gout study results for pozdeutinurad
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Formation Bio establishes USD600m debut fund for drug development
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
MetaVia announces presentation of DA-1726 Phase 1 data at Precision Liver Symposium
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials
US WorldMeds acquires Orbus Therapeutics
DifGen Pharmaceuticals completes European Decentralised Procedure for Tafamidis 61 mg Capsules